Immune-epithelial dual-targeting bilirubin nanoparticles for acute lung injury - PubMed
6 hours ago
- #nanoparticles
- #targeted therapy
- #lung injury
- Novel hyaluronic acid-bilirubin nanoparticles (HB@BN) were developed for targeted treatment of acute lung injury (ALI).
- HB@BN targets inflamed lung tissue via CD44 receptors to modulate immune responses and epithelial barrier repair.
- The nanoparticles utilize bilirubin's antioxidant properties to scavenge ROS and activate the Nrf2/HO-1 pathway, reducing oxidative stress.
- In vitro studies showed HB@BN shifts macrophages toward an anti-inflammatory phenotype, dampening immune activation.
- In a mouse ALI model, aerosolized HB@BN improved lung retention, reduced edema, inflammation, and tissue damage.